Aspirin in Primary Prevention: Needs Individual Clinical Judgments.
About:
This article is published in The American Journal of Medicine.The article was published on 2020-02-01 and is currently open access. It has received 3 citations till now. The article focuses on the topics: Evidence-based medicine & MEDLINE.read more
Citations
More filters
Journal ArticleDOI
Aspirin for Primary Prevention in Adults Older than 70 Years is Not Supported by High-Quality Trial Data and May Cause Harm.
Book ChapterDOI
Central Nervous System
TL;DR: In this paper, the authors describe central nervous system (CNS) complications of cancer commonly presenting to the emergency department, including altered mental status, high intracranial pressure/brain herniation, status epilepticus (convulsive and nonconvulsive), acute ischemic stroke, intra-cranial hemorrhage, and cerebral venous sinus thrombosis.
Journal ArticleDOI
The resolution of the Expert Council on current issues of the use of acetylsalicylic acid for the purpose of primary prevention of cardiovascular diseases in the light of new scientific data and updated clinical guidelines
O. Drapkina,T. V. Vavilova,Yuri Karpov,Zh. D. Kobalava,Nikita V. Lomakin,А.I. Martynov,E. V. Roitman,Dmitriy A. Sychev +7 more
TL;DR: Drapkina et al. as mentioned in this paper presented an expert opinion on the Russian National Association for Thrombosis and Hemostasis (NATH) and the Russian Society for the Prevention of Non-Communicable Diseases (ROPNIZ).
References
More filters
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
TL;DR: In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.
Journal ArticleDOI
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Donna K. Arnett,Roger S. Blumenthal,Michelle A. Albert,Andrew B. Buroker,Zachary D. Goldberger,Ellen J. Hahn,Cheryl Dennison Himmelfarb,Amit Khera,Donald M. Lloyd-Jones,J. William McEvoy,Erin D. Michos,Michael D. Miedema,Daniel Muñoz,Sidney C. Smith,Salim S. Virani,Kim A. Williams,Joseph Yeboah,Boback Ziaeian +17 more
TL;DR: Patrick T. O’Gara, MD, MACC, FAHA, Chair Joshua A. Beckman,MD, MS, FAha, Chair-Elect Glenn N. Levine, MD., Immediate Past Chair Sana M. Al-Khatib, MD.
Journal ArticleDOI
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Louise Bowman,Marion Mafham,K Wallendszus,William M. Stevens,Georgina Buck,Jill Barton,Kevin T. Murphy,Theingi Aung,Richard Haynes,Jolyon Cox,Aleksandra Murawska,Allen Young,Michael Lay,Fang Chen,Emily L. Sammons,Emma Waters,Amanda I Adler,Jonathan Bodansky,Andrew Farmer,Roger McPherson,Andrew Neil,David Simpson,Richard Peto,Colin Baigent,Rory Collins,Sarah Parish,Jane Armitage +26 more
TL;DR: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events.
Journal ArticleDOI
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
J. Michael Gaziano,J. Michael Gaziano,J. Michael Gaziano,Carlos Brotons,Rosa Coppolecchia,Claudio Cricelli,Harald Darius,Philip B. Gorelick,George Howard,Thomas A. Pearson,Peter M. Rothwell,Luis M. Ruilope,Michal Tendera,Gianni Tognoni +13 more
TL;DR: The event rate was much lower than expected, which is probably reflective of contemporary risk management strategies, making the study more representative of a low-risk population.